MHI-MS Successfully Tests Proof of Concept of Innovative V2X System in Singapore JCN Newswire

MHI-MS Successfully Tests Proof of Concept of Innovative V2X System in Singapore

October 6, 2022
TOKYO, Oct 6, 2022 - (JCN Newswire via SEAPRWire.com) - Mitsubishi Heavy Industries Machinery Systems (MHI-MS), a Mitsubishi Heavy Industries (MHI) Group company, has developed and successfully tested proof of concept of a Vehicle-to-Everything (V2X) system(1). The development program was carried out in collaboration with Mitsubishi Heavy Industries Asia Pacific (MHI-AP) and Nanyang Technological University, Singapore (NTU Singapore). The proof of concept was implemented on the NTU Singapore's Smart Campus from May to August 2022, and utilized NTU's Roadside Unit (RSU) and MHI-MS's multi-use in-vehicle device (onboard device, or OBD) to confirm vehicle tracking and activation of alarms from the RSU.COSMO program provides a comprehensive suite of technologies, solutions, and best-of-breed V2X mobility use casesCorrelation Diagram of Eight Work Packages on COSMO Program - This development program was under the WP8Under the development program, software related to MHI-MS's OBD wireless communication (dedicated short-range communication, or DSRC(2)) were developed to support V2X. By utilizing the same hardware, tolling and V2X communication applications can be operated simultaneously, enabling monitoring of traffic flow in real time. In time, the newly developed system will also support advanced traffic management such as giving priority to emergency vehicles and city bus, and safe driving such as timely distribution of traffic information to each vehicle. These improvements will both enhance motorist satisfaction and contribute to the creation of safe and smooth vehicle traffic infrastructure.The development program is conducted under the Connected Smart Mobility (COSMO) program(3), a national initiative hosted by NTU Singapore to develop next generation connected mobility technologies and solutions and to establish Singapore as a global hub for V2X research and commercialization. MHI-MS is also part of the COSMO consortium, which convenes leading industry partners, research organizations and public stakeholders to facilitate knowledge sharing, establish partnerships and pooling of resources to develop Intelligent Transport Systems (ITS) that make road traffic safer and more efficient for motorists.Going forward, MHI-MS will further dedicate its resources to V2X research and development of advanced ITS to provide optimal solutions for traffic and environmental issues around the globe.(1) V2X is a generic term for forms of communication between vehicles and various things (pedestrians, infrastructure, networks, etc.).(2) DSRC is a wireless communication method used in ITS. It is used for narrow range communication such as between roadside unit and onboard device.(3) The COSMO program was launched in November 2019. It aims to create safer and more efficient intelligent transportation systems through the formation of partnerships and sharing of information. The program is supported by Singapore's Agency for Science, Technology and Research (A*STAR) under its RIE2020 Advanced Manufacturing and Engineering (AME) Industry Alignment Fund - Pre Positioning (IAF-PP) (Grant No. A19D6a0053).About MHI GroupMitsubishi Heavy Industries (MHI) Group is one of the world's leading industrial groups, spanning energy, smart infrastructure, industrial machinery, aerospace and defense. MHI Group combines cutting-edge technology with deep experience to deliver innovative, integrated solutions that help to realize a carbon neutral world, improve the quality of life and ensure a safer world. For more information, please visit www.mhi.com or follow our insights and stories on spectra.mhi.com. Copyright 2022 JCN Newswire. All rights reserved. (via SEAPRWire)
More
Kashifu Inuwa: Putting NITDA on the Cusp of a Revolution ACN Newswire

Kashifu Inuwa: Putting NITDA on the Cusp of a Revolution

September 29, 2022
LAGOS, NIGERIA, Sep 29, 2022 - (ACN Newswire via SEAPRWire.com) - Nothing offers a more reliable picture of a country's economic performance better than a periodic assessment of sectoral contribution to Gross Domestic Product (GDP). It's no less so in Nigeria where a report by the National Bureau of Statistics indicates that Nigeria's Information and Communications sector contributed 18.44 percent to the GDP in the second quarter of 2022. The figure was an improvement from the 15 percent performance recorded in the last quarter of 2021.Kashifu Inuwa, NITDA Director-General: "Globally, there is a shortage of talents, so, we are creating a mandate to develop a talent strategy because we have a competitive advantage as a country with our vast human and natural resources. Nigeria can seize the opportunity to fill that gap" [Image: NITDA 2022]A little context will help put the significance of this growth in real perspective. The NBS data shows that the country's Information and Communications sector's contribution trumped the figures recorded by sectoral powerhouses such as Oil and Gas, Manufacturing, Real Estate, and Financial and Insurance. The plaudits - or a huge part thereof - for that sterling performance should go to the Ministry of Communications and Digital Economy, its helmsman Professor Isa Ali Ibrahim and the National Information Technology Development Agency (NITDA), and its steerer, Mr. Kashifu Inuwa Abdullahi.NITDA, as the Federal Government Agency responsible for the development of the Information Technology sector in Nigeria, it is one of the seven agencies under the Ministry of Communications Technology and Digital Economy.NITDA's impressive scorecard could be glimpsed also in how quickly it has been able to develop strategies, to help grow the Nigeria information technology ecosystem in a COVID and emerging post-COVID era. Under its dynamic and innovation-driven Director-General, Kashifu Inuwa, so much has been achieved by the Agency in a short span of three years.The NITDA Director-General, who recently marked three years in office, has gradually realigned and re-positioned the Agency, aiming to grow its capacity to respond adequately to the changing conditions and complexities of a digital economy in a fast-evolving global and local digital market.Milestones achieved under the leadership of Inuwa have been multi-faceted and stand out as bold testaments of his commitment to innovation. Inuwa's vision for NITDA in the medium term is encapsulated in a robust and bold policy framework - the Strategic Roadmap and Action Plan (SRAP, 2021 - 2024), which was launched last year.SRAP is designed to support the even broader, National Digital Economy Policy and Strategy (NDEPS) enunciated by the Ministry of Communications and Digital Economy.The many achievements recorded so far belie the fact that NITDA has implemented SRAP for just one year, a development that Inuwa recalls with an understandable pride: "The first year of implementing the NITDA Strategic Roadmap and Action Plan (2021 - 2024) has been one of deep learning, overcoming challenges and celebrating amazing breakthroughs. Along the way we got conferred with the prestigious National Productivity Order of Merit (NPOM) award, in recognition of our productivity, hard work and excellence in service delivery."In June 2021, the Agency started operating the National Public Key Infrastructure (PKI) with the Key Generation and Handover Ceremony for Root Certification Authority (RCA) for Country Signing Certification Authority (CSCA) and Country Verification Certification Authority (CVCA) of the Federal Republic of Nigeria. The NITDA Director-General remains upbeat about its prospects: "This unprecedented cybersecurity landmark (NDEPS Pillar 6) will not only close loopholes in online activity but significantly reduce system vulnerabilities that are exploitable by threat actors." That was undoubtedly a milestone achievement for Nigeria's digital space.To further close out loopholes in online activity and generate proper accreditation of professionals, the Agency intends to implement seven cybersecurity interventions that are focused on the PKI.A key component of this creative platform is that, it will coordinate the management of the Country Object Identifier (OID), and upgrade the PKI authentication infrastructure, create a PKI Audit requirement for Microsoft onboarding on operating systems, and integrate PKI with major hardware/software vendors. "We will then construct, furnish, and equip two National Cybersecurity Research Centers," Inuwa says.With regard to the expected outcome, Inuwa, reputedly Nigeria's first Cisco-Certified Internetwork Expert (CCIE) public servant, says: "Digitalisation of Government processes facilitates transparency, efficiency, productivity, participation, inclusiveness, cost savings, and competitive advantage, which ultimately translates to social and economic development for a country like Nigeria."He also estimates that the "implementation of Enterprise Content Management (ECM) can save Nigeria N4.5bn annually". For a government determined to curb corruption and cut costs, this is quite significant. Some of NITDA's action plans in the area of regulation and framework development, which are already in the works, include fostering Gender Digital Inclusion, enthroning a seamless e-Commerce environment and enhancing government digital services."In 2022, we are developing the Framework on Gender Digital Inclusion (GDI), with the aim of codifying learning standards for different categories of IT learners, while addressing the wide gender disparities in digital literacy and skill acquisition," he said.He is optimistic that the Guidelines for e-Commerce in Nigeria will provide an enabling framework for e-commerce to thrive and increase online trade's contribution to Nigeria's GDP. Just as crucial, he noted, is the planned development of the "Framework and Regulations for Implementing Government Digital Services (GDS) as a Guideline for Federal Public Institutions (FPIs) to deliver digital services and the Framework for Implementation and Compliance with relevant regulations to ensure compliance with all developmental regulatory instruments such as the NDPR, Cloud Computing, outsourcing, among others".To some, these goals may seem rather grandiose. But Inuwa possesses a tapestry of experience as an IT professional, having worked, and indeed excelled, in highly challenging environments, among which are the Central Bank of Nigeria and Galaxy Backbone Limited. This imbues him with a capacity to sufficiently address current developments and discern the dynamic trends and markets in the IT sector. His deep knowledge of IT trends reflects in the remarkable way he has steered the Agency to address the likely challenges of tomorrow's digital environment.Under Inuwa, NITDA has issued 966 digital tools and supported the development of digital transformation plans in accordance with NDEPS Pillar 5 in 3 states. "These digital tools and expert guide, which are part of our initiative to develop a framework and implementation toolkits for measuring the impact of digital technology deployment in FPIs are already enabling institutions to embark on digital transformation self-assessments," he said, regarding the feat.When Inuwa assumed office as NITDA's Director General in mid-2019, the global Covid-19 pandemic which led to the lockdown of several cities worldwide, including Nigeria, was only a few months away. When it hit the country in February 2020, prompting a government-ordered lockdown in April 2020 which lasted for several months, the Agency initiated and adopted several remote and contactless digital technologies that ensured government machinery kept working throughout the critical period. Inuwa set up a team called Tech4Covid to cushion the effects of Covid-19. This led to the identification of three innovations that helped curb Covid-19 and the establishment of a virtual academy for research and training with over 70 active courses and over 485,000 active students.In the circumstances, Inuwa's leadership and managerial skills which had been honed by several high-level trainings in leadership and management at reputable world-class institutions such as Harvard, Sloan Business School, London Business School, IMD Business School, Oxford University, Massachusetts Institute of Technology and Cambridge University, all came into play, ensuring that critical digital services are being delivered to government and that government can continue to perform its various functions effectively. The same expertise has come into play in his relentless efforts, to transform the Agency into a world class IT Agency.One instance of this transformation is the service delivery. The Director General comments: "In terms of the service contract, we reviewed the existing SERVICOM unit, expanded stakeholder identification, introduced new roles, realigned responsibilities to absorb the changes, created a new identity tagged iServe, and completed a sensitization process with key action points. Today, iServe represents our people first commitment to customer satisfaction through innovation and professionalism as we pursue the digital economy goals."Another key part of NITDA's statutory mandate is massive upskilling and reskilling of Nigerians across all walks of life. NITDA under Inuwa, has trained well over half a million Nigerians in various basic digital skills and literacy, with such diverse backgrounds as junior schoolteachers, traditional rulers, journalists, youth and talent development programme participants, among others.The Agency has embarked on a journey to train 1 Million Software Developers in the next 18 months, in collaboration with global giants such as Microsoft, Google, and other key ecosystem players. "Globally, there is a shortage of talents, so, we are creating a mandate to develop a talent strategy because we have a competitive advantage as a country with our vast human and natural resources. Nigeria can seize the opportunity to fill that gap", the NITDA, DG says, with high optimism.At a higher level, NITDA has awarded over 450 scholarships in IT to deserving Nigerians at the master's degree level, with 42 Phds, in the past few years. Inuwa is delighted with the phenomenal growth of the Nigerian Digital Innovation Ecosystem. Recent large acquisitions such as Stripe's $200 million takeover of Paystack in 2020, the $320 million Main One Ltd take over by US-based Equinix, and Flutterwave's $3.5 billion valuation have proudly spotlighted the country as a notable digital innovation centre in Africa.In the first half of this year alone, Nigeria's Digital technology and innovation startups have raised over one billion dollars in venture capital funding from major Western capital market funds. Notable among them are Sudo Africa, $3.7 million, Casava, $4 million, DrugStoc, $4.4 million, Bamboo, $15 million, Credpal, $15 million, and Reliance Health, $40 million.NITDA itself, has recently facilitated the support of six digital information technology start start-ups to access grants of $120 thousand each, amounting to $715 thousand. The Agency is actively backing several digital innovation hubs and has set up such hubs around the country, including over 150 start ups which it has supported to attend the GITEX global exhibition, World Creativity Challenge, among others.Just the beginning of this year, NITDA facilitated the approval of three Federal Executive Council memos through the Ministry of Communications and Digital Economy, in favour of digital startups. These approvals will incentivise and further harness the country's digital innovation and entrepreneurship ecosystem to create job opportunities for its teeming youth population.Within three years, Inuwa has equipped 160 digital economy centres around the country to further catalyze skills development and digital innovations. According to Statista, 35 million Nigerian internet users will be added by 2026, which is another clear indication of increasingly phenomenal growth in internet adoption and usage in Nigeria.Addressing the recent Ogun State Digital Summit in Abeokuta, on Digital Technologies: Key to Sustainable Development, Inuwa affirms that "Digital Technology innovation is not only booming, but it is also quickly moving towards sustainable solutions, with many of the most promising ideas from businesses worldwide having a clear focus on the environment."An innovation powerhouse, Inuwa would yet, undoubtedly, be pushing forward the boundaries of innovative digital technologies in Nigeria and beyond, in the coming years.Written by Iklima MusaLagos, Nigeria 28/09/2022. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Pagoda Celebrates the 6th New Retail Anniversary: Fulfillment of ESG Philosophy with Consistent Efforts on Customer-centric Management ACN Newswire

Pagoda Celebrates the 6th New Retail Anniversary: Fulfillment of ESG Philosophy with Consistent Efforts on Customer-centric Management

September 20, 2022
HONG KONG, Sep 20, 2022 - (ACN Newswire via SEAPRWire.com) - Lately, Pagoda, China's biggest fruit chain retailer, released its 6th New Retail Anniversary Report. The report suggests steady growth in Pagoda's new retail business, as evidenced by over 15 million app downloads, 47 million mini program subscribers and over 5.4 million store community users hitherto in online operation. During this year's August 18 anniversary promotion, Pagoda's GMV in online operation hit CNY 30 million within two days merely.For years, Pagoda has been invariably upholding the philosophy of customer-centric management, whereby Pagoda stands out in the competition with a development framework featuring comprehensive distribution channels, a variety of categories and first-rate services.In terms of distribution channels, Pagoda has established a neighborhood-based fruit retail chain model with characteristics of online/offline integration, store/warehouse integration, timely delivery and next-day delivery, among which, next-day delivery is defined as one of the key businesses this year. By leveraging infinite space for the display of more commodities for sale online, Pagoda furnishes customers with a wide selection of items. Up to now, the next-day delivery business has been available in 30 cities nationwide.In terms of product, Pagoda builds quality fruit brands with utmost efforts, including 27 knock-outs and level A product brands; its fresh product brand "Panda Master" has originated 185 products falling into rice, flour, grain & oil, meat, poultry, egg & milk, quick-frozen food, condiments, etc.In terms of services, Pagoda keeps putting into practice the return policy "fruit can be returned without the receipt, physical object or reason". In 2021, Pagoda's refund amount represented only 0.15% of its revenue. Granting customers the decision power of return, Pagoda's "heart-to-heart retail" has hereby been recognized by consumers. Winning consumer confidence, Pagoda reins in its management cost with effectiveness.As an advocate of long-term development, Pagoda is in a constant quest for fulfillment of ESG philosophy, with a view to the sustainable development of enterprise, agriculture, ecology and society.In terms of social responsibility, Pagoda has a firm conviction that "it's better to pass on fishing skills than to hand out fish". Its holding subsidiary Fruit Ally assigns its tech team to help establish poverty alleviation bases and impart planting knowledge to local fruit farmers, under Pagoda's support in marketing, commercialization and branding.Moreover, Pagoda takes multi-pronged measures, such as the introduction of BLOF technology and use of soil analysis and fertilization design, to effectively address soil problems including pathogens, hardening and salinization, etc.; making allowance for physiological growth characteristics of different crops, Pagoda deploys compost, microorganism and systemic fertilization for organic farming, so as to produce eco-friendly and nutritive agricultural products with high quality and yield but low cost.BLOF-based "Three-Zero" vegetables are now in seasonal crop rotation across partnering bases. "Three-Zero" vegetables feature zero fertilizer, zero pesticides and zero hormones throughout plantation and production. To carry out the philosophy of rural vitalization with efficiency, Pagoda is deepening government-enterprise cooperation as well. In July this year, Pagoda concluded a strategic contract with Ningxia Department of Agriculture and Rural Affairs, with intention of facilitating the local implementation of BLOF technology and making "Three-Zero" vegetables exemplify the quality agricultural products of Ningxia.Pagoda Founder & CEO Yu Huiyong said, Pagoda plans to expand to more provinces and municipalities nationwide to help boost China's agriculture in the future, using management methods built up in years of practice. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
G20 Digital Innovation Network (DIN): Catalyst for Digital Economy Growth in Indonesia ACN Newswire

G20 Digital Innovation Network (DIN): Catalyst for Digital Economy Growth in Indonesia

September 19, 2022
Nusa Dua, Bali, Sep 19, 2022 - (ACN Newswire via SEAPRWire.com) - The G20 Digital Innovation Network (DIN) meeting is able to be a catalyst to expedite the digital economy sector development in Indonesia, said Minister Johnny G Plate, Indonesian Ministry of Communication and Informatics (KOMINFO). The event aims to bring together start-ups, venture capital companies, policy makers, as well as leading global technology enterprises, including Google.Minister of Communication and Information Johnny G. Plate delivered his remarks at the opening of the G20 Digital Innovation Network (DIN) forum in Nusa Dua, Badung, Bali, Saturday (September 3, 2022). (ANTARAFOTO/Aditya Pradana Putra/rwa.)"We believe that the DIN event is an important catalyst for the growth of the digital economy by strengthening collaboration among start-ups, venture capital companies, as well as national and international corporations," the minister said in his opening remarks at the inauguration of G20 DIN, a High-level Side Event of the 2022 G20 Digital Economy Working Group (DEWG), in Nusa Dua, Bali.Before the G20 ministers and international organization representatives present, Plate noted the development of the digital economy in Indonesia shows a positive trend. "In 2021, the value of the digital economy in Indonesia reached US$70 billion and it will increase to US$315,5 billion in 2030. This potential is Indonesia's future economy (strength) which is supported by various well-performed start-ups," he said.Plate said that currently, Indonesia has two decacorn start-ups, or companies whose valuations have reached US$10 billion, and more than 10 unicorn start-ups, which have valuations of at least US$1 billion. Plate believes that start-ups play an important role in determining the development of the digital economy sector, both at the domestic and regional levels."I trust the G20 DIN (organizing committee) to carry out this series of meetings and discussions which are expected to encourage various collaborations on digital innovations," Plate stated.The G20 DIN meeting was held in the Bali International Convention Centre (BICC) in Badung District from September 2 to 4, 2022. More than 400 participants attended the event in person, while another 200 participated in the event virtually.Chairperson of 2022 G20 DIN, Sonny Hendra Sudaryana, said at a press conference after the inauguration that the implementation of 2022 G20 DIN would focus on five priority sectors: education technology, financial inclusion, healthcare, supply chain, as well as green and renewable energy.2022 DIN Start-Up Awards Winners:1. Healthcare -- UCARE.AI, Singapore / Neurobots, Brazil2. Supply Chain -- MOOVA, Argentina / Sinbad, Indonesia3. Green & Renewable Energy -- Xurya, Indonesia / Uali, Argentina4. Edutech -- Edubuk, India / Accredify, Singapore5. Financial Inclusivity -- WireBarley, South Korea / Lendo, Saudi ArabiaFavourite Start-Up Winners:1. Healthcare -- NUSANTIC, Indonesia / Qapsula, Russia2. Supply Chain -- Eunimart, India / FairSupply, Australia3. Green & Renewable Energy -- EINHUNDERT Energie GmbH, Germany / MVL Labs, South Korea4. Edutech -- Cakap, Indonesia / Sarente Gameon, Turkey5. Financial Inclusivity -- Komunal, Indonesia / Lendo, Saudi ArabiaG20 Digital Innovation Network: https://g20innovationnetwork.orgSource: DIN, Indonesian Ministry of Communication and Informatics (KOMINFO). Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech at ESMO Congress 2022 – New Data Shows 100% Oncology Trials Growth in APAC ACN Newswire

Novotech at ESMO Congress 2022 – New Data Shows 100% Oncology Trials Growth in APAC

September 5, 2022
SYDNEY, Sep 5, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO, will attend ESMO Congress 2022 with new data showing Asia Pacific has seen a 100% growth in oncology trials during 2017 to 2021 and contributes to more than a third of the global clinical development of immune-oncology drugs.Novotech has experienced CRO operations across APAC and the US offering a unique and unparalleled suite of services for early to late phase biotech clinical research.The clinical data compiled by GlobalData for Novoteoch also found that: "By the end of 2021 40% of active immuno-oncology clinical trials involved at least one location in the Asia-Pacific region, with majority of trials conducted in China, followed by Australia, South Korea, Japan and Taiwan. In the APAC region, the proportion of oncology trials doubled during 2017-2021. In China, the growth in oncology trials was associated with a significant increase in cancer incidence, development of innovative products by domestic companies, focus on immune-oncology, and leadership in cell therapy."Download the Reports Here:IMMUNO-ONCOLOGY - ASIA PACIFIC - CLINICAL TRIAL LANDSCAPE https://novotech-cro.com/whitepapers/immuno-oncology-asia-pacific-clinical-trial-landscapeEVOLUTION OF CLINICAL TRIALS IN THE ASIA PACIFIC REGION COMPARED TO THE US AND THE EU5 https://novotech-cro.com/whitepapers/evolution-clinical-trials-asia-pacific-region-compared-us-and-eu5According to Yooni Kim, Vice President, Global Clinical Services Novotech: "Asia-Pacific offers a compelling solution for expedited clinical trials with its vast patient populations, less competitive clinical trial landscape, and world-class KOLs, in addition, regulatory reforms have accelerated approval processes. Novotech's service delivery model is tailored to the needs of biotech clients. Our local teams have exceptional site and investigator access, our project management approach emphasizes problem-solving, ownership and flexibility, and our investments in data and technology ensure clients have real-time access to trial performance."Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, and has signed 45 Leading Site Partnership agreements over the last 3 years.About Novotech Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Transcenta Holding (06628): Product pipeline progressing well with significant competitive differentiation ACN Newswire

Transcenta Holding (06628): Product pipeline progressing well with significant competitive differentiation

September 1, 2022
HONG KONG, Sep 1, 2022 - (ACN Newswire via SEAPRWire.com) - As pharmaceutical reformation is underway, the importance of the innovative strength of biotech companies has become increasingly prominent, the entire industry has also formed a completely different pattern from ten years ago. Today, differentiation has also become the general trend of the industry. Photo: Transcenta's Pipeline, Source: Company websitePhoto: Transcenta's ICB Platform, Source: Company websiteAs the interim results of Hong Kong companies have recently been announced, we might as well look for potential targets from the announcements that aim to differentiate themselves and truly bet on innovation. We found that Transcenta Holding (06628) might be worthy of attention. Transcenta has a strong focus on innovative research and development, well advanced in international clinical trials, while having multiple competitive advantages. Let's take a look at this Company. Dr. Caroline Germa, Transcenta's new CMO, accelerates the development of differentiated pipelinesThe core of differentiation in the industry is First-in-class and Best-in-class. In terms of pipelines, Transcenta has injected significant innovative attributes, developing the most innovative drugs such as FIC/BIC, highlighting the advantages of differentiated clinical strategy and development, which is expected to facilitate the pipeline product approval and commercialization and address the unmet medical needs.Moreover, it can also be seen from the clinical trial overview that Transcenta's new drug development is more oriented towards global strategy, targeting the interests of the global market, and basically the product canddiates of the Company are being developed in parallel in both China and the US. This advantage is also based on the fact that the Company has a very efficient team in bothUS and China, with a deep understanding of the industry, covering all aspects of discovery, research and clinical trial development and manufacturing.The majority of Transcenta's executives have a background of 15-20 years in leading pharmaceutical companies, with proven track record and a well-balanced combination of expertise spanning research, clinical development, manufacturing, strategic planning and financing. At the same time, the Company has a scientific advisory team of internationally renowned experts and industry elites. In the process of moving into the global "blue ocean", the Company is also gradually developing and growing, attracting more outstanding talents to join. Recently, the Company welcomed a new CMO, Dr. Caroline Germa, as the Company's Executive Vice President of Global Drug Development and Chief Medical Officer. As a leader in oncology and drug development, Dr. Germa has a high reputation in the industry, and her personal strength has been proven by many achievements. Dr. Germa has worked for AstraZeneca, Bristol-Myers Squibb (BMS), Novartis and several other internationally renowned pharmaceutical companies, and has accumulated considerable industrial experience, also involved in the development and research of a number of blockbuster drugs including Ribociclib and Neratinibfor breast cancer.Dr. Germa's joining Transcenta Holding will undoubtedly provide a great boost to the Company's innovative development. In the future, with her contacts in the pharmaceutical industry and her unique and profound understanding, she will better lead Transcenta's global expansion and make a significant contribution to enhancing the Company's shareholder value in the future. It is not difficult to find that the Company's team with high qualifications and deep background has laid a solid foundation for the global application and clinical development of its innovative pipeline molecules.At present, Transcenta has built a diversified and risk-balanced pipeline of antibodies with best-in-class or first-in class potential in therapeutic areas with high unmet medical needs, including oncology, kidney and bone diseases. Most of these molecules are discovered and developed in house. Specifically, the Company's oncology product pipeline targets major cancer pathways which have potential synergistic mechanisms of actions for tumor indications, which is precisely the most differentiated design of the Company's oncology pipelines. Moreover, the Company has developed non-oncology pipeline strategy, which plays in a field facing less competition and reach high market potentials.It is worth to mention that the drug discovery technology of Transcenta Group is particularly impressive. Based on the unique IMTB antibody discovery platform, the company has developed a number of antibodies targeting various pooled sites above a particular target, thereby expanding the selectivity of its drug candidates. The Company has generated and is developing oncology products such as TST001, TST005, TST003 and TST010 through the IMTB technology platform. In the future, more valuable innovative drugs will be discovered and filed for global registration, helping Transcenta Group to become a leading global biotechnology company.Rapidly advancing product pipeline, leading the world in clinical progressThe strength of Transcenta Holding is not only reflected in the layout and research and development of innovative drugs, but also in the Company's ability to execute and facilitate clinical trials. In the first half of 2022, the Company actively advanced its product pipeline and achieved remarkable results. In particular, the Company's flagship product, TST001, ranked second in the world in terms of clinical progress and will soon enter Phase III clinical trials.Claudin18.2 has relatively high expression in gastric cancer, pancreatic cancer, esophageal cancer and bile duct cancer, and TST001 has high biological activity, affinity and NK cell activity, and has ideal efficacy and safety. It has a considerable commercial application prospect. At the same time, the Company has also developed a specific antibody for companion diagnostics and will use this Claudin18.2 immunohistochemical assay to support international clinical trial registration. The Company is also well ahead of schedule and at the forefront of the world in this area.In developing TST001, Transcenta has, on the one hand, continued to explore multiple tumor types. On the other hand, the Company is also experimenting with TST001 combination regimens, and its clinical progress is likewise world-leading. Let's keep an eye on its mid-term phase 2 clinical data for TST001 and chemotherapy combination in frontline gastric cancer patients as the company disclosed it will be published soon in a major European clinical oncology conference. This could be important to understand the potential of TST001.Not only that, the Company's other pipelines are also progressing smoothly, including the bifunctional humanized antibody TST005 targeting both PD-1/PD-L1 and TGF-beta pathways, the candidate product TST002, a humanized sclerostin mAb for the treatment of osteoporosis, and a high affinity humanized monoclonal antibody TST003 (FIC) and TST004, a humanized MASP-2 mAb candidate for kidney diseases. It is worth mentioning that the Company's first-in-class targeting Gremlin1(TST003), a preclinical asset with antitumor activities in multiple difficult to treat tumor models were published in the international oncology authoritative journal "Nature Cancer". In addition, the Company has also developed a series of relatively early pipeline products, which further enriched the Company's product pipeline. As these candidate products gradually enter the clinic stages and are successively approved in the future, the Company's intrinsic value will gain more impetus.Actively promoting CDMO business to fully realise the source of income and reduce expenditureIn addition to product development, Transcenta Holding has also forward-looking in the layout of commercial production. It can be seen from the Company's results announcement that Transcenta has established a complete CMC and production platform, both for early cell line process development and GMP mass production systems, which are designed by the Company and met international standards.Transcenta Holding utilises a novel integrated continuous bioprocessing platform (ICB) for developing robust production processes, formulations and analytics, manufacturing drug products throughout product life cycle. The advantages of the Company's ICB platform are significant, as its capacity is more than 10 times higher than the traditional Fed-batch flow addition process, and its cost has been significantly reduced by almost 50%. In May 2022, Transcenta had successfully passed audit by the European Union Quality Person (QP). This combination of quality and cost advantages supports the clinical studies and registration of the Company's candidate products worldwide.In addition, Transcenta has leveraged its CMC capabilities and the potential value of its ICB platform to further expand its CDMO business. While the CDMO business has enabled the Company to achieve open source and cost savings, it has also attracted the attention of international high-quality partners by virtue of the high-quality industry reputation accumulated in the client, and further expands international cooperation. The Company has been developing and collaborating commercially with Merck for an industry-first disposable flow-through polishing system, and maintains a domestic leading position in the field of perfusion technology.SummaryAll in all, the interim results announcement of Transcenta Holding has many highlights and the Company's competitive advantages are distinct. Whether it is drug discovery, clinical development, or commercial production, it has strong strength in all aspects. We believe that with the successful development and commercialization of the Company's innovative and differentiated products, Transcenta will achieve leapfrog development and is worthy of long-term attention. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

TANAKA Memorial Foundation to Offer Precious Metals Research Grants of up to 5 Million Yen

September 1, 2022
TOKYO, Sep 1, 2022 - (ACN Newswire via SEAPRWire.com) - The TANAKA Memorial Foundation (Representative Director: Hideya Okamoto) announced that it will take applications for research themes for FY2022 Precious Metals Research Grants between September 1 (Thu) and November 30 (Wed). Applications will be accepted from Japanese educational institutions and public research institutes conducting research and development using precious metals. In this 24th year of the research grant, recipients will receive 5 million yen for the Platinum Award, 2 million yen for the Gold Award, 1 million yen for the Silver Award, 1 million yen for the Young Researcher Award, and 300,000 yen for the Encouragement Award.Applications for the Precious Metals Research Grants are open to themes in all fields related to new technology and research and development in which precious metals can make a contribution. Applications can be submitted using the application form on the TANAKA Memorial Foundation website ( https://tanaka-foundation.or.jp ), and, after strict examination, award recipients will be announced at the end of March 2023.The TANAKA Memorial Foundation aims to contribute to the development and cultivation of new fields for precious metals and to the development of science, technology, and the social economy by conducting activities that enable more people to experience a prosperous society. This program is being implemented to help support the various challenges faced in the "new world opened up by precious metals." Last year, the research on "Enhancing development of model-based design and production technologies for electronic parts containing precious metals" won a Gold Award for being able to significantly contribute toward the development of processing technologies and improvement of performance through the development of model-based designs using numerical analysis methods - represented by methods such as the finite element method - to minimize cost and takt time related to product design, prototyping, and process design. Another Gold Award was presented for research and development on "Formation of backside power delivery network using precious metal wires" related to the formation of precious metal wires, which is an element technology for three-dimensional mounting that is gaining attention as an integration technology for advanced logic devices.Overview of the 2022 Precious Metals Research GrantsTheme:- Themes that involve any of the following: new technologies to which precious metals can make a contribution, research related to precious metals that will bring innovative evolution to products, or research and development of new products using precious metalsGrant Amounts:- Platinum Award: 5 million yen (1 award)- Gold Award: 2 million yen (1 award)- Silver Awards: 1 million yen (4 awards)- Young Researcher Awards: 1 million yen (2 awards)- Encouragement Award: 300,000 yen (several awards)* The grant amount is treated as a scholarship donation.* Awards may not be granted in some cases.* The number of awards is subject to change.Eligible Candidates:- Personnel who belong to (or work for) educational institutions in Japan (universities, graduate schools, or technical colleges) or public and related research institutions may participate.* As long as the applicant is affiliated with a research institution in Japan, the base of activity can be in Japan or overseas.* The Young Researcher Awards are for researchers under the age of 37 as of April 1, 2022.Application Period:- 9am, September 1, 2022 (Thu) - 5pm, November 30, 2022 (Wed)Application Method:- Enter the required information on the application form available on the TANAKA Memorial Foundation website ( https://tanaka-foundation.or.jp ) and upload details of the research (papers and supplementary material on the theme).Announcement:- Results will be announced on the TANAKA Memorial Foundation website around the end of March 2023.* TANAKA will contact the award recipients directly.Conditions:Research content that falls under any of the following- New technology related to precious metals- Research and development related to precious metals that bring about innovative evolution in products- Research and development of new products using precious metals* Precious metal refers to eight elements of platinum, gold, silver, palladium, rhodium, iridium, ruthenium and osmium.* If development is conducted jointly (or planned to be) with other material manufacturers, please indicate so.* Products that have already been commercialized, put to practical use, or that are planned are not eligible.Inquiries Concerning the Research Grant Program:Precious Metals Research Grants OfficeGlobal Marketing / R&D Supervisory Department, TANAKA Kikinzoku Kogyo K.K.22F Tokyo Building, 2-7-3 Marunouchi, Chiyoda-ku, Tokyo 100-6422E-mail: joseikin@ml.tanaka.co.jpTANAKA Memorial Foundation website: https://tanaka-foundation.or.jpTANAKA Memorial FoundationEstablished: April 1, 2015Address: 22F Tokyo Building, 2-7-3 Marunouchi, Chiyoda-ku, TokyoRepresentative: Hideya OkamotoPurpose of Business: To provide grants for research related to precious metals to contribute to the development and cultivation of new fields for precious metals, and to the development of science, technology, and the social economy.Areas of Business: Provision of grants for scientific and technological research related to precious metals. Recognition of excellent analysis of precious metals and holding of seminars and other events.TANAKA Kikinzoku Kogyo K.K.Headquarters: 22F, Tokyo Building, 2-7-3 Marunouchi, Chiyoda-ku, TokyoRepresentative: Koichiro Tanaka, Representative Director & CEOFounded: 1885Incorporated: 1918Capital: 500 million yenEmployees: 2,429 (as of March 31, 2022)Sales: JPY 389,646,820,000 (FY2021) Main businesses: Manufacture, sales, import and export of precious metals (platinum, gold, silver, and others) and various types of industrial precious metals products. URL: https://tanaka-preciousmetals.com* From the current consolidated fiscal year, the amounts of sales for some transactions are indicated as net values due to application of the Accounting Standard for Revenue Recognition.Press InquiriesTANAKA Holdings Co., Ltd.https://tanaka-preciousmetals.com/en/inquiries-for-media/This press release in PDF: https://www.acnnewswire.com/docs/files/20220901_EN.pdf Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Pursued progress while ensuring stability and built up momentum, Legend Holdings realized revenue of RMB237,685 million in the first half of 2022

August 31, 2022
HONG KONG, Aug 31, 2022 - (ACN Newswire via SEAPRWire.com) - Legend Holdings Corporation (stock code: 3396.HK) announced today the unaudited condensed consolidated interim results for the six months ended June 30, 2022 (the "Reporting Period"). During the Reporting Period, the Company's revenue was RMB237,685 million and the net profit attributable to equity holders of the Company amounted to RMB2,131 million.Mr. Li Peng, Executive Director and CEO of Legend Holdings, said that in the face of the complex international environment, in the first half of 2022, Legend Holdings pursued progress while ensuring stability, and deepened the strategic thinking of "industrial operation, technological innovation", made steady improvement in its corporate competitiveness and operational efficiency, and further strengthened its investment and layout in the field of science and technology innovation; At the same time, we gave full play to the role of "chain leader", practiced the concept of green development, actively fulfilled corporate social responsibility, and devoted ourselves to contribute to the high-quality development of China's economy.During the Reporting Period, Legend Holdings further consolidated the foundation of its industrial operations and strengthened its operational management. The revenue of the segment increased by 4% year-on-year to RMB235,775 million, and the net profit attributable to the equity holders of Legend Holdings increased by 20% year-on-year to RMB2,830 million. -- Lenovo achieved revenue and profit growth for the ninth consecutive quarter. While maintaining its position as the world's No.1 PC maker, Lenovo accelerated the development of new growth drivers with the revenue share of the non-PC business reaching a new high of 37% in the second quarter-- Levima Group took the lead in achieving import substitution in the field of EVA photovoltaic materials. In the first quarter, the upgrading and transformation of EVA devices realized the expected effect, and the result in the second quarter reached a new high. In addition, the company continued to focus on the field of new materials, advancing the new projects in an orderly manner, and entered the field of electronic specialty gas; -- The core business of Joyvio Group develops well as a whole. Joy Wing Mau continued to improve its vertically integrated fruit supply chain and achieved rapid growth in revenue. Global demand and prices for seafood products continued to rebound, and the revenue and profit of Joyvio Food have been improved; -- With a healthy core capital adequacy ratio and strong international credit ratings, Banque Internationale a Luxembourg S.A. ("BIL") achieved solid growth - successfully navigating the challenges faced by Europe's economy. Meanwhile, BIL obtained QFLP status in Shenzhen, through which it will further support the introduction of foreign capital into China's market and other initiatives.During the Reporting Period, the industrial incubations and investments segment delivered stable and sound growth despite capital market volatility.-- Legend Capital raised funds of RMB3.5 billion, invested in 26 new projects, and 4 portfolio companies went public; -- Legend Star invested in nearly 20 new projects, more than 40 enterprises under management completed their next funding round, and it exited approximately 10 projects. The first round closing of the firm's fifth USD fund and the final closing of its artificial intelligence special fund were also completed.; -- Fullhan Microelectronics's market share has significantly increased, and its performance has achieved growth. It continued to invest in mid- and high-end surveillance products to enhance profitability, and the expediting growth of smart home & smart automotive products has served as new driving engines;-- Lakala maintained China's No. 2 operator in terms of bank card transaction volume and leading operator in QR code payments. At the same time, it proactively provided technological support for other businesses; -- The production and operation of Eastern Air Logistics have recovered steadily and achieved steady improvement in performance; -- Zhengqi Holdings focused on the field of scientific and technological innovation, carried out industrial exploration and investment layout, and has so far helped 11 of its portfolio companies in total successfully go public; -- JC Finance & Leasing achieved solid performance and year-on-year revenue growth amid the pandemic.Increasing investment in scientific and technological innovation, adhering to innovation-driven development and continuously supporting the growth of Specialized and Innovative EnterprisesLegend Holdings stays true to its original aspiration of "revitalizing the country through business". It has further increased its investment in technological innovation in line with the national strategy of achieving high-quality development driven by technological innovation and has achieved promising results. -- Steady implementation of the "plan of doubling investments in Research and Development"In the first half of 2022, Legend Holdings' Family Group's total R&D investment (excluding the capitalized R&D spending) reached RMB7.212 billion, and currently owns over 20,000 granted patents, ranking top among Chinese enterprises in various patent awards. Lenovo remains committed to its plan of doubling investments in R&D; it increased R&D spending by 23% year-on-year and grew R&D headcount by 29% year-on-year. Levima Advanced Materials adhered to its innovation-driven strategy. During the Reporting Period, it completed the laboratory R&D development for 9 new products and processes, the production technology formulas for 15 new products, and the industrialization of 5 new products. -- Continuously "long-sought" in the field of science and technology In the first half of 2022, Legend Holdings' family group invested in nearly 50 new technology companies, covering multiple fields such as cutting-edge technologies, hard & core technologies, healthcare and medicine, and has contributed to the development of specialized and innovative enterprises in China through its empowerment. During the year as of August 15, 2022, 12 of its portfolio companies have successfully completed IPOs. Close to 50 of Legend Holdings' family group's portfolio companies made the newly announced list of the fourth official list of state-level specialized and innovative enterprises, such as Noitom, Hua Kong Tsingjiao, Spacety, Union Semiconductor, EasyDiagnosis Biomedicine, NuVolta Technologies, etc. Up to now, Legend Holdings' family group has nearly 100 specialized and innovative companies in its portfolio.Adhering to green growth, playing the full strength as a chain leader, and actively fulfilling corporate social responsibilityLegend Holdings is committed to promoting green development philosophy through the efforts of its portfolio companies to seize the green development opportunities, and jointly build an ecological civilization. Lenovo has set a goal of net-zero carbon emissions by 2050, transforming into "net-zero carbon emission plants" on the basis of its state-level green plants. The Company continues to create and provide smart solutions that facilitate the green transformation, empowering over 300 top industrial enterprises in China. Levima Advanced Materials focused on the development of new energy materials and biodegradable materials on top of its existing EVA photovoltaic film business; BIL helped Chinese companies issue overseas green bonds to facilitate the development of green finance; at the same time, Legend Capital, Legend Star, Zhengqi Holdings, etc. have further expanded investments in related fields to promote innovation and technological progress.In terms of industrial chain, Legend Holdings promoted its subsidiaries to give full play to their advantages in operations and supply chains and assisted the coordinated development across the industrial chains. Lenovo was named a Gartner Global 25 Supply Chain for the eighth consecutive time. 90% of its manufacturing was from China, with 2,000 level-1 suppliers, directly providing more than 350,000 jobs. Levima Advanced Materials continued to make efforts in the field of new materials, expanding vertically to the upstream of the industrial chain while horizontally expanding to new segments, driving the mutual development with SMEs.Corporate social responsibility is an important part of Legend Holdings' overall strategy. The Company actively responds to the national call to steadily promote the implementation of the national employment stabilization policy within the family group, and carefully formulated and closely tracked various recruitment plans. While extensively attracting social talents, it focused on the recruitment of fresh graduates from colleges and universities, and actively expanded the scale of recruitment. In terms of public welfare undertakings, Legend Holdings has long focused on key areas such as fostering start-ups, contributing to rural revitalization, promoting social integrity and responding to disasters for years and insists on investing and carrying out relevant work effectively.Mr. Ning Min, Chairman and Executive Director of Legend Holdings, said that, under the strong leadership of the Communist Party of China's Central Committee, China coped well with the changes in the international environment, and achieved economic and social development while effectively coordinating pandemic prevention and control, adhering to the guiding ideology of "people-centered", and achieved a series of results in various tasks, which also created a good environment for the development of enterprises. In the first half of 2022, the Company continued to improve its position, strengthen its capabilities, seize the important opportunities arising from the transformation and upgrading of Chinese enterprises, focus on the real economy, increase efforts in the field of scientific and technological innovation, and earnestly fulfill its corporate social responsibilities. In the future, we will continue to aim at accomplishing the great goal of building a world-class enterprise, and contribute to the journey of achieving high-quality development and common prosperity! Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Arrows Agency Expands Global Marketing Powerhouse SeaPRwire

Arrows Agency Expands Global Marketing Powerhouse

August 29, 2022
NEW YORK, NY, August 29, 2022 – (SEAPRWire) – The Arrows Agency, a digital marketing and advertising agency, has launched a global expansion of its award-winning client services. Headquartered in New York City, the agency now covers North America, Europe, Middle East, and Asia. To learn more about The Arrows Agency, visit https://arrowsagency.com/ Founded by former executives in media, advertising, and global business advisory, Arrows takes a solutions-driven approach to developing bespoke growth programs for clients in industries ranging from CPG to AI. The agency focuses on building brands and expanding sales for clients through studying trends, understanding consumer behavior, staying on the cutting edge of innovation and creativity, and embracing data analytics. The team behind Arrows has been responsible for $350MM in revenue generated for their clients, facilitating over $250MM of investments, and amassing over four billion impressions. The agency’s current roster of clients ranges from medium to large enterprise companies. The founders have previously worked with many prestigious brands in entertainment, technology, luxury resorts, banks, major record labels, and film studios. Arrows offers clients complete omnichannel support through a spectrum of marketing and advertising services including: marketing consulting and strategy, business development, market research and surveys, PR, branding, social media, influencer campaigns, social media management, PPC/Paid media, paid social advertising, web development, eCommerce development, content creation, and creative design. According to a report from McKinsey, companies spend $1 trillion on marketing globally. The amount of revenue businesses allocate to marketing has increased steadily over the past 10 years, with average marketing percentage of revenue landing around 13% in 2021, compared to just 8% back in 2011. More than half of businesses surveyed plan to spend more time and money on marketing and web development in the next year. Media contact Brand: The Arrows Agency Contact: Sam Goldsmith, VP of Communications E-mail: sam.goldsmith@arrowsagency.com Website: https://arrowsagency.com/ Address: 99 Hudson Street, New York, NY 10013, USA Telephone: +1 800-348-3170 SOURCE: The Arrows Agency The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
Blockchain Development Company EvaCodes Raises $500,000 from Web3-oriented Hypra Fund SeaPRwire

Blockchain Development Company EvaCodes Raises $500,000 from Web3-oriented Hypra Fund

July 27, 2022
MIAMI, FL, July 27, 2022 – (SEAPRWire) – Blockchain development company EvaCodes raises a $500,000 round from the Web3-oriented hypra.fund. EvaCodes is a blockchain development company that provides Web3 development services for startups and enterprises interested in creating new products and services using blockchain. The company was founded in 2019 by two serial entrepreneurs and blockchain enthusiasts, Yehor Havrylenko and Vitalii Basiuk. Over the last year, EvaCodes has developed and launched more than 50 projects in the Web3 and blockchain industries. The agency provides a wide range of services. Among them are Cryptocurrency Development, Smart Contracts, Tokens and Tokenomics, dApps, DeFi and Fintech products, Digital Banking Products, NFT Marketplaces, and NFT Collections, Cryptocurrency Wallets and Exchanges, Metaverse development, EVM, L1/ L2, Play to Earn and other blockchain games, Real Estate Blockchain platforms, crypto trading bots and other products related to the blockchain industry. EvaCodes developed these projects using different blockchains: Ethereum/ Solidity, Solana/ Rust, Binance Smart Chain, Polygon, Near and other chains. The Web3-oriented hypra.fund was founded in March 2022 by Ukrainian investor Igor Pertsiya (ex-TAventures and CEX.io) and IT entrepreneur Dmitry Volkonsky (TRIONIKA). Besides investments, the fund helps companies get to the next level in operational processes, select an effective team, find the best tools for growth, and raise funding rounds. One of the features of the fund is that they build and develop projects with founders. “As a fund, we are creating our own ecosystem, where in addition to financial investments, consulting on scaling, and team development – we propose technical product development teams. EvaCodes has established itself in the market and has shown that its team has strong expertise in blockchain development and a vast number of successful cases under its belt. That is why we decided not only to invest but also to make EvaCodes a key technical element of the fund,” says Igor Pertsiya, partner and co-founder of hypra.fund. Yehor Havrylenko, CEO at EvaCodes says, “As the industry continues to evolve, the demand for quality Web3 products and skilled blockchain developers grows daily. We are grateful to the hypra.fund team for their trust, and hope that working together will bring fruitful results for both teams. We plan to use the money from the investment round to expand our business and attract new blockchain engineers and grow our client portfolio. Over the next 3-5 years, EvaCodes plans to launch its own products and startups using blockchain technology. One of those planned is Dating-to-Earn – an NFT Tinder. More announcements will be made soon.” About EvaCodes EvaCodes is a full-stack blockchain development agency focused on providing blockchain development services and building Web3 products. With its headquarters in the USA and development centers across Poland, Estonia, Ukraine, Armenia, and the USA, EvaCodes provides blockchain development services for their customers to create outstanding market-disrupting blockchain products. EvaCodes is a top-rated blockchain development agency reviewed by Clutch(5.0), GoodFirms (5.0), and Upwork (44 projects and 100% job success rate). Website: https://evacodes.com LinkedIn: https://www.linkedin.com/company/evacodes About hypra.fund Hypra.fund is a $25m Web3-oriented joint venture fund investing in and building projects with founders. Besides investments, the venture fund proposes ready-to-work blockchain development teams, helps companies reach a new level in operational processes, select an effective team, find the best tools for growth, and raise funding rounds. Website: https://hypra.fund Twitter: https://twitter.com/hypra_fund Media Contact Brand: EvaCodes Contact: Kseniya Prydybailo, PR Supervisor Email: blockchain@evacodes.com Website: https://blockchain.evacodes.com/ SOURCE: EvaCodes The article is provided by a third-party content provider. SEAPRWire ( https://www.seaprwire.com/ ) makes no warranties or representations in connection therewith. Any questions, please contact cs/at/SEAPRWire.com Sectors: Top Story, Daily News SEA PRWire: PR distribution in Southeast Asia (Hong Kong: AsiaExcite, EastMud; AsiaEase; Singapore: SEAChronicle, VOASG; NetDace; Thailand: SEAsiabiz, AccessTH; Indonesia: SEATribune, DailyBerita; Philippines: SEATickers, PHNotes; Malaysia: SEANewswire, KULPR; Vietnam: SEANewsDesk, PostVN)
More
The 7th Quam IR Awards was Successfully Held ACN Newswire

The 7th Quam IR Awards was Successfully Held

July 27, 2022
HONG KONG, Jul 27, 2022 - (ACN Newswire via SEAPRWire.com) - The award presentation ceremony of Quam IR Awards 2021 ('QIRA' or 'The Awards') successfully took place on 27 July, 2022 at Four Seasons Hotel Hong Kong, recognizing investor relations professionals capable of assisting their companies in adapting to changes and, with outstanding governance thinking and practical strategies skills, taking their companies towards sustainable development in the ever-changing business environment. Management of Tonghai Financial Group, including, Mr. Stacey Wong, Chief Operating and Risk Officer, (fifth from the left), Mr. Chris Wu, Chief Financial Officer (second from the right) , Mr. Army Yan, Chief Investment Officer of Tonghai Financial Group (first from the left) and Ms. Sandy Lam, Managing Director of Hong Kong Sustainability Strategic Advisory Limited (second from left), took picture together with award presenters and representatives of awarded companies.Celebrating IR Excellence Quam IR Awards is proud to recognize and reward the very best listed company in the investor relations industry. The winners of the QIRA have opened the door of communication through diversified channels, representing the tact and professionalism of investor relations. The keen enthusiasm for the 7th Quam IR Awards can be seen from the entries. A total of 15 companies have differentiated themselves from their competitors to win the Awards. Partnered with Professional Institution, Giving Commendations to Sustainable Companies With the environment, social and governance becoming increasingly important factors that affect the strategies and operation of listed companies, China Tonghai IR has partnered with Hong Kong Sustainability Strategic Advisory Limited (HKSSA), an advisory firm focusing on enterprises' abilities of their sustainable development, granting "Sustainable Development Category" - Platinum, Gold, Silver and Bronze awards from a professional perspective to honour companies demonstrating excellence in all 3 areas of ESG. In particular, a special award "Sustainable Development Category - The Best Report of the Year" has been added this year. It is delighted to announce Lenovo Group Limited becoming the first awarded company to achieve this honor. Quality Enterprises Further Reinforce Hong Kong's Position as International Financial CentreMr. Chris Wu, Chief Financial Officer of Tonghai Financial Group, said in the opening remark "The winning companies demonstrate the multiplicity, dynamics, outstanding corporate governance and culture of the business community of Hong Kong. Together with these important elements, it enhances Hong Kong's status as International Financial Center, meanwhile, it brings additional economic activities to the capital markets." Mr. Stacey Wong, Chief Operating and Risk Officer of Tonghai Financial Group, said "Hong Kong has made a tremendous effort in introducing emerging and high growth companies onto the stock exchange, like the acceptance of weighted voting rights, pre-revenue biotech companies and SPAC. There has also been an increasing number of dual listings of US-listed Chinese companies. We are certain that more companies, in the old and new economy alike, will be attracted to Hong Kong. You from the investor relations profession play a vital role in educating investors on the potential and development of business models new to them, as well as resuscitate the value of old economy companies."Unwavering Support from Business Community and Media friends Tonghai IR was honoured to invite Mr. Joseph Chan, JP, Under Secretary for Financial Services, Dr. Anthony Fan, Founding President of The Hong Kong Independent Non-Executive Director Association, Dr. Michael Chan, Honorary Chairman of Hong Kong Institute of Marketing and Dr. Sam Kwok, President of Hong Kong Society of Economists as our guests of honour to witness such grand occasion. The 7th Quam IR Awards came to a successful conclusion, thanks to our supporters in the business community, media friends and sponsors in Hong Kong and mainland China. Our supporting media partners include The Chamber of Hong Kong Listed Companies, The Hong Kong Independent Non-Executive Director Association, Ming Pao, The Standard, FX678 and StockStar. Tonghai IR is grateful for the strong support and generous sponsorship from Green Common and HKTaxi, which make Quam IR Awards 2021 a success.The list of awardees for Quam IR Awards 2021 (In alphabetical order of company name):Stock Code / Company NameHong Kong Index Constituents (Hand Seng Index) Category2020 ANTA Sports Products Limited 2382 Sunny Optical Technology (Group) Company LimitedMainboard Category1761 Babytree Group0081 China Overseas Grand Oceans Group Limited 1929 Chow Tai Fook Jewellery Group2232 Crystal International Group Limited 0173 K. Wah International Holdings Limited 0826 Tiangong International Company LimitedSustainable Development Category - Platinum3311 China State Construction International Holdings Limited2232 Crystal International Group Limited0992 Lenovo Group LimitedSustainable Development Category - Gold2020 ANTA Sports Products Limited 3718 Beijing Enterprises Urban Resources Group Limited0081 China Overseas Grand Oceans Group Limited Sustainable Development Category - Silver1761 Babytree Group1229 Nan Nan Resources Enterprise Limited0152 Shenzhen International Holdings LimitedSustainable Development Category - Bronze0227 First Shanghai Investments Limited 2266 Lai Si Enterprise Holding LimitedSustainable Development Category - The Best Report of the Year0992 Lenovo Group LimitedWebsite of Quam IR Awards 2021: https://eventedm.tonghaiir.com/QIRA2021-22/EN_US/For enquiries, Tonghai IRMarketing & PR contact:Mandy Lo T: 2217-2753 Email: mandy.lo@tonghaifinancial.comCharlie Chan T: 2217-2504 Email: charlie.chan@tonghaifinancial.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

The Global Pharmaceutical Industry is Accelerating; Aptorum Group Has Received Orphan Drug Designation from US FDA for Its SACT-1

July 27, 2022
HONG KONG, July 26, 2022 - (ACN Newswire) - The aging of the population is accelerating, pharmaceutical technology is constantly updating, and the development of the global pharmaceutical industry continues to accelerate. The pharmaceutical market is expected to maintain a growing trend. According to Frost & Sullivan, the global pharmaceutical market is expected to reach $1,711.4 billion by 2025. Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through (i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. discovery and development of new small molecules and biologics, and systematic screening of existing approved drug molecules, etc.; and (ii) the co-development of a novel molecular-based rapid pathogen identification and detection diagnostics technology with Accelerate Technologies Pte Ltd, the commercialization arm of the Singapore's Agency for Science, Technology and Research. Currently, Aptorum Group's R&D pipelines cover the ALS family of drugs and the SACT family of drugs, covering such indications as drug-resistant Staphylococcus aureus (including MRSA), Gram-positive cocci, influenza A, COVID-19, orphan disease neuroblastoma and other cancers. Since the beginning of this year, Aptorum Group has accelerated its research and development (R&D), with major breakthroughs achieved in several pipelines under development. SACT-1, the Group's orally administered small molecule drug for the treatment of neuroblastoma, was granted its first patent by the United States Patent and Trademark Office (US PTO) in November 2021 and Orphan Drug Designation by the US Food and Drug Administration (FDA) at the beginning of this year. Meanwhile, the Group completed the Phase I clinical trial of SACT-1 in January this year and announced the finalized data in May. The data showed that SACT-1 had impressive safety and good tolerability making the later stages of SACT-1 promising. In addition, earlier in the year, the Group launched oncology and autoimmune discovery and development platform targeting unmet mutations and novel biomarkers, focusing on indications including non-small cell lung cancer ("NSCLC") and autoimmune diseases such as lupus, rheumatoid arthritis and inflammatory bowel diseases. In the meantime, the Group also completed a Phase I clinical trial for ALS-4, a first-in-class anti-virulence-based small molecule drug targeting infections caused by Staphylococcus aureus including MRSA. In the second quarter of this year, the Group's Rapid Pathogen Infectious Disease Liquid Biopsy Diagnostics ("RPIDD") was granted a patent by the US PTO, and the Group is spearheading the efforts in the ongoing clinical validation and pre-commercialisation preparation of the technology. Currently, the overall development prospect of the biopharmaceutical industry is promising. Aptorum Group is actively advancing its R&D projects. With its strong R&D capabilities and internal management capacity, it is expected to further enhance its business development, expand the room for enterprise development, and gain greater development opportunities in the biopharmaceutical industry.
More
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer ACN Newswire

Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer

July 26, 2022
Foster City, CA, and Hangzhou, China, Jul 26, 2022 - (ACN Newswire via SEAPRWire.com) - Apollomics Inc. an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced the appointment of Jane Wang, PhD as Chief Scientific Officer. In this role, Dr. Wang will lead the drug discovery pipeline for the Company. She will also serve as Apollomics' China General Manager and will report to the Chief Executive Officer. "We are very excited to have Jane join our team," said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "Jane is a drug discovery expert in a number of therapeutic areas, including oncology, with a proven track record advancing compounds from the laboratory to clinical development. With her broad experience, she will make significant contributions to our global research strategy.""I am pleased to join a Company dedicated to the discovery, research, and clinical development of novel agents targeting multiple oncology indications. I look forward to growing our global team to discover and advance new compounds into the clinic," added Jane Wang, Ph.D., Chief Scientific Officer. Dr. Wang brings over 20 years of drug discovery experience in the biopharmaceutical industry. Most recently, she served as Vice President, Medicinal Chemistry at WuXi AppTec where she worked to enhance RNA drug discovery and led multiple teams in medicinal chemistry and synthetic organic chemistry. Prior to WuXi, Dr. Wang spent 12 years on the drug discovery team at Pfizer, Inc. as a senior principal scientist, focusing on diseases in oncology, inflammation, and the central nervous system Previously, she did her postdoc at the U.S. National Institute of Health and at Schering-Plough. Dr. Wang earned a Ph.D. from the University of Maryland Baltimore County and a B.S. in Applied Chemistry from Fudan University. She is an inventor/co-inventor of over 50 patent applications and an author of over 35 publications. About Apollomics Inc.Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting and immuno-oncology agents. The Company's product pipeline has several programs at different stages of development, including a novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, California, USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.Contact Information:Investor Contact:Raymond LowVP Finance, Corporate Controller(925) 451-0712Raymond.Low@apollomicsinc.comU.S. Media Contact:Remy BernardaCorporate Communications(415) 203-6386remy.bernarda@apollomicsinc.comChina Media Contact:Porda Havas International Finance Communications GroupKelly FungGeneral Manager(852) 3150 6763kelly.fung@pordahavas.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea ACN Newswire

Novotech Client SK bioscience Achieves SKYCovione(TM) COVID-19 Vaccine Approval in Korea

July 13, 2022
SEOUL, S.KOREA, Jul 13, 2022 - (ACN Newswire via SEAPRWire.com) - Novotech, the leading Asia Pacific biotech specialist CRO which has recently expanded its services to the US, congratulates its client SK bioscience on the recent COVID-19 vaccine licence approval.SK bioscience and GSK recently announced the successful authorization:SK bioscience announced that 'SKYCovione(TM),' South Korea's first COVID-19 vaccine candidate adjuvanted with GSK's pandemic adjuvant has been authorized by the Korean Ministry of Food and Drug Safety (KMFDS). South Korea has become one of the few countries in the world to have both a domestically developed COVID-19 vaccine and a treatment.SKYCovione(TM) is a self-assembled nanoparticle vaccine targeting the receptor binding domain of the SARS-CoV-2 Spike protein for the parental SARS-Cov-2, jointly developed with the Institute for Protein Design (IPD) at the University of Washington School of Medicine with combination of GSK's pandemic adjuvant. The development of SKYCovione(TM) has been supported by funding from the Bill & Melinda Gates Foundation and Coalition for Epidemic Preparedness Innovations (CEPI). The results of the Phase III clinical trial, collected in 4,037 adults over 18-year-old, showed that SKYCovione(TM) induced neutralizing antibody responses, against the SARS-CoV-2 parental strain. The neutralizing antibody titres increased about 33 times compared to before the injection and were 3 times that of AstraZeneca's Vaxzevria(TM), the control vaccine used in the study, 2 weeks after the second dose.The clinical trial was conducted in cooperation with 16 institutions, including Korea University Guro Hospital and IVI (International Vaccine Institute), a non-profit international organization.SK bioscience will apply for authorizations at other selected regulatory agencies for distribution of SKYCovione(TM), including through the COVAX Facility and for emergency use listing (EUL) to the World Health Organization (WHO).SKYCovione(TM) is based on recombinant protein vaccine technology which has been used for development of current vaccines including influenza, hepatitis B, and HPV. SKYCovione(TM) can be stored in normal refrigeration conditions from 2 to 8 degrees Celsius, so it is particularly suitable for use in low-income settings without the need for ultra-cold chain facilities.The market expects that SKYCovione(TM) will accelerate securing of Korea's vaccine sovereignty and reducing dependence on vaccine imports.Jaeyong Ahn, CEO of SK bioscience said, "The development of Korea's first COVID-19 vaccine was achieved based on the efforts of the government and members who have been working hard all day and night. We will continue to work with various global organizations based on our own research and manufacturing technologies to preemptively respond to new pandemics."See full press release here https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=132&Dr. John Moller, CEO Novotech said, "As the lead CRO managing the Phase lll study in six APAC countries, the entire team at Novotech congratulates SK bioscience for such an outstanding clinical success and subsequent licence approval. Licence approval is the ultimate goal in clinical research and drug development and we are honoured to be part of the process of bringing new life-saving therapies to market. We look forward to working with SK bioscience on further vaccine developments in the near future."About NovotechNovotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit https://novotech-cro.com/contactMedia ContactDavid JamesE: communications@novotech-cro.comAU: +61 2 8218 2144 USA: +1 415 951 3228Asia: +65 3159 3427 Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
IBO Technology Achieves Turnaround in FY2021/22 Annual Results ACN Newswire

IBO Technology Achieves Turnaround in FY2021/22 Annual Results

July 3, 2022
HONG KONG, Jul 3, 2022 - (ACN Newswire via SEAPRWire.com) - IBO Technology Company Limited ("IBO Technology" or the "Company", together with its subsidiaries, the "Group"; Stock Code: 2708.HK) is pleased to announce its consolidated annual results for the year ended 31 March 2022 (the "financial year" or the "Year"). During the Year, thanks to the rapid development of its principal businesses, the Group was able to achieve a business turnaround. IBO Technology's three main businesses are 5G (communication equipment and private network solutions), Information Technology Application Innovation ("ITAI") IT (terminal products and industry solutions) and Internet of Things ("IoT") (products and solutions), and is committed to providing quality one-stop 5G, ITAI and IoT products and solutions. During the Year, thanks to the recovery in economic activities and the expansion of customer base, the Group delivered accelerated growth and achieved business turnaround. Its revenue amounted to approximately RMB1,046.30 million, representing a year-on-year surge of 86.7% from approximately RMB560.33 million in the previous year. The gross profit of the Group increased by 53.9% to approximately RMB178.60 million (FY2020/21: approximately RMB116.02 million), while the gross profit margin was 17.1% (FY2020/21: 20.7%). The profit attributable to owners of the Company for the financial year was approximately RMB14.66 million, as compared to loss attributable to owners of the Company of approximately RMB42.10 million in FY2020/21. The basic earnings per share for the financial year was approximately RMB2.67 cents, as compared to the basic loss per share of approximately RMB9.81 cents in the previous year.Capitalising on favourable policies in ITAI industry and industry digitisation to achieve business growthFrom the "13th Five-Year Plan" to the "14th Five-Year Plan", the Central and local governments have been developing the "digital economy" and building "Digital China" as their important objectives, clarifying the "Digital China" construction strategy and seizing the high ground of the digital economy production chain. The governments at all levels are strongly promoting the development of the ITAI industry, facilitating the development of various fields within the industry and driving the transformation of the traditional IT information industry.With the rapid growth of China's ITAI industry and its penetration into various fields, key core technologies have been researched and developed domestically to foster original innovations. The Central and local governments have made great efforts to promote the ITAI procurement, and are determined to increase the proportion of ITAI product applications, which have begun to enter key industry markets such as finance, telecommunications and energy. The enlarged scale of procurement for domestically-produced equipment as well as software and hardware by all levels, coupled with the expanding market size, have reflected that replacement by domestic production has entered a substantive stage. Riding on the "14th Five-Year Plan" policies, the Group has been proactively growing its ITAI business, which is divided into direct sales and Original Design Manufacturer ("ODM") channels according to its sales model, and actively participating in proprietary tendering to accelerate the launch of its products which have been widely recognised.Striding into harvesting period as intelligent terminal products sales and software development businesses achieved significant breakthroughIntelligent terminal products sales business remained the Group's main revenue source, accounting for 85.2% of the total revenue for the financial year. During the Year, the Group focused on the development, production and sales of customised IoT smart terminals for its customers, mainly including notebooks, tablets, all-in-one PCs, desktop PCs, and industrial gateway servers. Benefiting from the recovery of economic activities and the favourable policies of the ITAI industry at the national level, coupled with the orders of ITAI IT products signed earlier by the Group were gradually delivered to customers, the revenue from the sales of intelligent terminal products increased significantly. During the Year, the intelligent terminal products sales business recorded a revenue of approximately RMB891.37 million, representing a significant increase of approximately 121.7% and the growth driver of the Group.In respect of software development business, the Group planned and designed the software system frameworks and function lists for customers, and provided customised software application development services based on their business and management needs. The software development business accounted for 10.0% of the Group's total revenue. Leveraging its strong software development capabilities, the Group has been providing quality software application development services to serve customers in different industries for many years. In addition to maintaining long-term and strategic relationships with existing customers, the Group also actively explores new customers to expand its customer base and drive sales. During the Year, as a result of the continued expansion of its software development business and its customer base, the Group recorded revenue of approximately RMB104.23 million (FY2020/21: RMB45.49 million), representing a significant year-on-year increase of approximately 129.1%.With regards to system integration business, based on the analysis and assessment of customers' needs, the Group provides customers with integrated and customised system solutions based on IoT and related technologies. In view that the revenue of the systems integration business is derived from one-off projects with fluctuating revenue as compared to other segments, the Group's systems integration business shrank during the financial year, with revenue slightly dipped to approximately RMB39.82 million (FY2020/21: approximately RMB101.00 million), accounting for 3.8% of the Group's total revenue.For system maintenance services business, the Group provides software and hardware system maintenance services for information systems, including system equipment maintenance and management, database maintenance, daily system monitoring and system upgrade, etc. During the Year, attributable to its business optimisation and adjustment, the Group's system maintenance services business decreased slightly to approximately RMB10.88 million (FY2020/21: approximately RMB11.83 million), accounting for 1.0% of the Group's total revenue.Accelerating the launch of products and riding on the favourable policies to promote exponential growth of the Group's businessRiding on the "14th Five-Year Plan" policies, the Group has been proactively expanding its ITAI business and actively participated in proprietary tendering to accelerate the launch of its products. During the Year, the purely domestically-produced notebook computers designed and developed by the Group have entered the market and have been widely recognised. The Group will accelerate the development of the ITAI industry as well as the research and development of products, striving to gain more market share as the Group's purely domestically-produced ITAI IT products are expected to become the growth engine of the Group's future results. While continuously improving its products, the Group will enhance its marketing and promotion efforts for ITAI IT products, and cooperate with industry partners to promote the sales of ITAI IT products of the Group and accelerate the rapid popularisation and promotion of replacement by domestic production in various industries.As a leading industry digital solutions provider, the Group has collaborated with a number of large state-owned enterprises and private enterprises through different projects and gained extensive project experience in the field of 5G private network. Looking ahead, the Group will build on its successful experience in previous projects and its solid foundation in the industry, as well as the synergies generated with enterprise partners in various aspects such as technology, supply chain and market to organise research and pilot testing for 5G private networks, to optimise the key stages ranging from application to deployment, in order to provide the best quality solutions to operators and industry partners.Mr. LAI Tse Ming, Chairman and Executive Director of IBO Technology, said, "Our three business segments are closely interconnected and synergistic in terms of underlying technologies, application technologies, supply chains, projects and business models. We strive to integrate and innovate the 5G, ITAI and IoT technologies to form new business models and industrial ecologies, so as to effectively leverage our advantages and integrated technological capabilities to maximise overall value created. In addition, we will actively identify suitable merger and acquisition targets that create strong synergies with our existing principal businesses to support our operations and rapid development. Leveraging the Group's accumulated technologies and strong market demand, our three principal businesses are expected to generate significant synergies, which will contribute to the exponential growth of the Group's overall business development. Going forward, the management will continue to seek breakthroughs and strive to create long-term and stable returns for our investors and shareholders."About IBO Technology Company LimitedIBO Technology Company Limited (Stock code: 2708.HK), a leading digital solutions provider, is principally engaged in providing 5G communication equipment and private network solutions, ITAI terminal products and industry solutions, IoT products and solutions, as well as industrial digital solutions in the PRC. The Group's businesses mainly cover four areas, namely (i) intelligent terminal products sales; (ii) system integration; (iii) software development; and (iv) system maintenance services. With nearly 20 years penetration in the IoT industry, the Group serves customers from both the public and private sectors in the PRC, including government authorities, large-scale state-owned enterprises and private enterprises.For more details, please visit: http://www.ibotech.hk/ Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Tianda Pharmaceuticals Annual Results 2022 ACN Newswire

Tianda Pharmaceuticals Annual Results 2022

June 30, 2022
HONG KONG, Jun 30, 2022 - (ACN Newswire via SEAPRWire.com) - Tianda Pharmaceuticals Limited (Tianda Pharmaceuticals or the Group, stock code: 0455.HK) is pleased to announce its annual results for the year ended 31 March 2022. During the Reporting Period, the Group's business attained further development as revenue reached HK$510.0 million for the Current Financial Year, representing an increase of 7.5% compared to last year. Innovation and R&D made steady progress with R&D expenses increasing 34.7% year on year (YOY) to HK$15.9 million. With cash and cash equivalents of approximately HK$334.0 million as of 31 March 2022, the Group has sufficient financial resources to support its business development. To celebrate the 10th anniversary of the change of the Group's name to "Tianda Pharmaceuticals Limited", the Board of Directors recommended the payment of a final dividend of HK0.26 cent per share and a special dividend of HK0.56 cent per share to reward its shareholders for their support and trust over the years.The new R&D and production base located in Jinwan, ZhuhaiThe Pharmaceuticals and medical technologies business revenue reached HK$396.1 million, an increase of 10.7% YOY. The Group focuses on products and technology, actively introducing, developing and acquiring innovative drugs, generic drugs, healthcare products, and medical devices for cardiovascular and cerebrovascular, women and children, and respiratory system diseases, oncology and rehabilitation. The Group's major product, Tuoping Valsartan capsules, a medicine for cardio-cerebrovascular disease, became the No. 1 product in its category in China by sales quantity as it seized the opportunity of the success in securing first place in the nation's Third Round of Centralized Drug Procurement with Target Quantity to supply nationwide, which increased both sales and brand awareness. Through the integration of sales teams and channels, the Group's medicines, especially the pediatric drugs, Tuoen Ibuprofen oral suspension and Ibuprofen suspension drops, also achieved satisfactory sales growth. The Group's new R&D and production base in Jinwan, Zhuhai has commenced operations, with an investment of HK$430 million for the first phase of the development and is equipped with imported and domestic advanced automated equipment. The new base is poised to become a pharmaceutical and health industry base with high standard, quality and efficiency through innovation development, accelerated product lines enrichment and production capacity improvement. Five CDMO/CMO contracts have been successfully signed.The Chinese medicine business revenue reached HK$106.5 million, down 4.9% YOY. In the first nine months of the Reporting Period, the Chinese medicine business achieved faster growth by utilizing various methods to form mutually beneficial cooperation with partners such as medicinal materials farmers, cooperatives, distributors and pharmaceutical companies for building a nationwide and global business network for the Chinese medicinal materials business. Going forward, the Group will adopt a variety-centric approach to focus on domestic and overseas trading of Chinese medicinal materials, production and sales of TCM decoction pieces and formula granules, and distribution business, integrating quality resources from upstream to downstream for the industry.The Medical and healthcare services revenue reached HK$7.4 million, an increase of 57.4% YOY. The Group steadily advances the development of the modern Chinese medical clinic "TDMall" through self-construction, franchising and mergers and acquisitions. The priority is to expand in the Guangdong-Hong Kong-Macao Greater Bay Area while making plans for a national and global rollout. TDMalls have been opened in Zhuhai, Hong Kong and Sydney successively since 2019 with the aim to build the global chain operation model under three different local laws and regulations for Chinese medicine. Meanwhile, Zhuhai TDMall became the first Chinese medicine clinic in the world to receive both the ISO 9001:2015 Quality Management System Certification and Qualicert International Service Quality Certification. As part of its caring for people's health and CSR initiatives, the Group launched the "TDMall Cloud-based Global Anti-epidemic Chinese Medicine Platform" amid the fifth wave of the COVID-19 pandemic in Hong Kong in early 2022 to support the Group's "Free Consultation and Medicine" charity campaign to provide the public with comprehensive remote Chinese medicine services from prevention, treatment to rehabilitation, as well as Chinese medicine services for mitigating long COVID.China's "14th Five-Year Plan" proposes to comprehensively promote the construction of a healthy China, placing the protection of people's health as a strategic priority for development and providing people with comprehensive life-cycle health services. Adhering to the corporate slogan of "Tianda for Health!", the Group will continue to execute the strategy of "development of Chinese medicine business as a foundation, development of innovative drugs and medical technologies, as well as development of quality medical and healthcare services", implementing the "3D+1S" initiatives (business development (BD), research and development (R&D), investment and development (ID), and marketing & sales (S)) working in tandem to continuously enrich product lines and improve the quality and quantity of R&D projects in the pipeline through an external introduction, R&D, and mergers and acquisitions (M&A), as well as to identify cutting-edge technologies and products and quality projects worldwide in an effort to achieve high-quality development, so as to make a greater contribution to safeguarding the health of mankind.About Tianda Pharmaceuticals LimitedTianda Pharmaceuticals Limited is engaged in the development of the Chinese medicine business as a foundation, development of innovative drugs and medical technologies, as well as development of quality medical and healthcare services, committed to becoming a leading pharmaceutical enterprise that sets its footholds in China while expanding its presence worldwide.For enquiriesTianda Pharmaceuticals LimitedInvestor Relations Department Phone: +852 2545 3313 Email: ir@tianda.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Argentine President Fernandez meets with Gotion High-tech chairman Li Zhen

June 28, 2022
HONG KONG, Jun 28, 2022 - (ACN Newswire via SEAPRWire.com) - On the afternoon of June 24, Argentine Time, Argentine President Alberto Fernandez met with Li Zhen, chairman of Gotion High-tech, and his delegation at the presidential residence in Olivos, he explicitly supported Chinese investment in Argentina, and praised Gotion High-tech's multiple industrial investments will promote the development of Argentina's new energy industry. The two sides also had friendly exchanges on the "Targets of Carbon Peak and Carbon Neutralization" strategy, the new energy vehicle industry, the Sustainable Transportation Act and the joint venture between Gotion High-tech and Corven, a well-known American auto parts manufacturer, to establish electric bus batteries and other topics.Alberto Fernandez:The friendship between China and Argentina goes back to ancient times. I attended the Beijing Winter Olympics this year and witnessed the unique Chinese winter Olympics moment. Not long ago, I also participated in the online communication of the BRICS Summit. China's "One Belt, One Road" strategy and "Targets of Carbon Peak and Carbon Neutralization" strategy have encouraged many Chinese enterprises to invest in Argentina, undertake photovoltaic power stations, hydropower DAMS and other new energy projects, and continue to promote them, it also brings opportunities for Argentina's development. The world is already shifting to renewable energy. Argentina has made incentives for lithium, wind power, photovoltaic and other industries. The Development of Sustainable Transport Act, introduced last year, it aims to promote investment in electric vehicles, promote the electrification of transport and provide legal protection for investors in new energy.We welcome Chinese investment in Argentina. Gotion High-tech's industrial investment activities in Argentina, cover the development, processing and battery products of lithium resources, which accelerates the development of local lithium resources and it will help the development and progress of Argentina's new energy industry.Li Zhen:Since the establishment of diplomatic ties between China and Argentina, leaders of the two countries have actively supported complementary advantages and economic cooperation between enterprises, especially the "Belt and Road" initiative. It provides strategic guidance, points out the direction and lays the foundation for inter-enterprise cooperation.The third energy revolution with solar and wind power as the main body has come. To make full use of it, we must have energy storage technology. Gotion High-tech has been focusing on energy storage for 16 years. We plan to reach 300GWh battery production capacity in the world by 2025, which makes enterprises' demand for lithium resources more vigorous.Argentina is the third-largest economy in Latin America, with a harmonious social system and orderly development of resources, it provides a good external environment for enterprises to invest in. We have partnered with Jujuy National Energy and Mining Company and we will work with Corven in Buenos Aires to develop downstream applications. In the next 100 years, new energy vehicles will certainly be a new engine for the world economy. Gotion is willing to work with visionary people in Argentina to jointly create a new era in the energy industry.Daniel Scioli, Argentina's minister of Production and Development, Ariel Schale, The industry minister, and President Fernandez were accompanied by Cecilia Todesca, Minister of International Economic Relations, and Fernanda Avila, Minister of Mines, and communicated with the Gotion High-tech team on the development of the lithium industry. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More

Argentine President Fernandez meet with Gotion High-tech chairman Li Zhen

June 28, 2022
HONG KONG, Jun 28, 2022 - (ACN Newswire via SEAPRWire.com) - On the afternoon of June 24, Argentine Time, Argentine President Alberto Fernandez met with Li Zhen, chairman of Gotion High-tech, and his delegation at the presidential residence in Olivos, he explicitly supported Chinese investment in Argentina, and praised Gotion High-tech's multiple industrial investments will promote the development of Argentina's new energy industry. The two sides also had friendly exchanges on the "Targets of Carbon Peak and Carbon Neutralization" strategy, the new energy vehicle industry, the Sustainable Transportation Act and the joint venture between Gotion High-tech and Corven, a well-known American auto parts manufacturer, to establish electric bus batteries and other topics.Alberto Fernandez:The friendship between China and Argentina goes back to ancient times. I attended the Beijing Winter Olympics this year and witnessed the unique Chinese winter Olympics moment. Not long ago, I also participated in the online communication of the BRICS Summit. China's "One Belt, One Road" strategy and "Targets of Carbon Peak and Carbon Neutralization" strategy have encouraged many Chinese enterprises to invest in Argentina, undertake photovoltaic power stations, hydropower DAMS and other new energy projects, and continue to promote them, it also brings opportunities for Argentina's development. The world is already shifting to renewable energy. Argentina has made incentives for lithium, wind power, photovoltaic and other industries. The Development of Sustainable Transport Act, introduced last year, it aims to promote investment in electric vehicles, promote the electrification of transport and provide legal protection for investors in new energy.We welcome Chinese investment in Argentina. Gotion High-tech's industrial investment activities in Argentina, cover the development, processing and battery products of lithium resources, which accelerates the development of local lithium resources and it will help the development and progress of Argentina's new energy industry.Li Zhen:Since the establishment of diplomatic ties between China and Argentina, leaders of the two countries have actively supported complementary advantages and economic cooperation between enterprises, especially the "Belt and Road" initiative. It provides strategic guidance, points out the direction and lays the foundation for inter-enterprise cooperation.The third energy revolution with solar and wind power as the main body has come. To make full use of it, we must have energy storage technology. Gotion High-tech has been focusing on energy storage for 16 years. We plan to reach 300GWh battery production capacity in the world by 2025, which makes enterprises' demand for lithium resources more vigorous.Argentina is the third-largest economy in Latin America, with a harmonious social system and orderly development of resources, it provides a good external environment for enterprises to invest in. We have partnered with Jujuy National Energy and Mining Company and we will work with Corven in Buenos Aires to develop downstream applications. In the next 100 years, new energy vehicles will certainly be a new engine for the world economy. Gotion is willing to work with visionary people in Argentina to jointly create a new era in the energy industry.Daniel Scioli, Argentina's minister of Production and Development, Ariel Schale, The industry minister, and President Fernandez were accompanied by Cecilia Todesca, Minister of International Economic Relations, and Fernanda Avila, Minister of Mines, and communicated with the Gotion High-tech team on the development of the lithium industry. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
Grand Ming Group Holdings Limited Announces Annual Results for the Year Ended 31 March 2022 ACN Newswire

Grand Ming Group Holdings Limited Announces Annual Results for the Year Ended 31 March 2022

June 24, 2022
HONG KONG, Jun 24, 2022 - (ACN Newswire via SEAPRWire.com) - Grand Ming Group Holdings Limited (the "Company" and together with its subsidiaries, the "Group", stock code: 1271.HK) today announces its annual results for the year ended 31 March 2022 ("FY 2021/22").Highlights-- Revenue amounted to HK$817.9 million, a decrease of 45.2% from the previous financial year.-- Net profit for the year was HK$17.5 million, representing a decrease of 88.2%.-- Proposed payment of final dividend of 4.0 HK cents per share.-- Stay positive toward lucrative business of owning and operating data centres via expanding portfolio of developing two new centres in near future.-- Seize opportunity to increase land reserve for property development in Hong Kong.-- Execute the plan for property development in Nanning, Guangxi Province, China targeting for luxurious senior residential market.The Group's consolidated revenue decreased approximately 45.2% from approximately HK$1,492.4 million for the year ended 31 March 2021 ("FY 2020/21") to approximately HK$817.9 million for FY 2021/22. The decrease was primarily caused by lower revenue recognised from the building construction project at Kai Tak which was at the completion stage during FY 2021/22.The Group's net profit for FY 2021/22 amounted to approximately HK$17.5 million, representing a decrease of 88.2% when compared to that of approximately HK$149 million for FY 2020/21. Earnings per share was 1.2 HK cents (2021: 10.5 HK cents). The deterioration in results for FY 2021/22 was attributed by (i) reduction of revenue and profit recognised from the Kai Tak construction project which was at the completion stage; (ii) lower profit attained from the sales of typical units of Cristallo project; and (iii) loss incurred in certain variation orders of a completed construction project. Disregarding the changes in fair value of investment properties, the Group recorded an underlying loss of approximately HK$75.2 million (FY 2020/21: underlying profit of HK$148 million). The Group believes a long-term high dividend policy is the best reward for our loyal shareholders. The Board now recommends to pay a final dividend for FY 2021/22 of 4.0 HK cents per share. Together with the interim dividend of 4.0 HK cents per share and special interim dividend of 20.0 HK cents per share already paid, the total dividends for FY 2021/22 amounted to 28.0 HK cents per share. During FY 2021/22, revenue derived from the construction business decreased by approximately 65.1%, from approximately HK$1,133.7 million for FY 2020/21 to approximately HK$395.5 million for FY 2021/22. The decrease was primarily attributed to lower revenue recognised from the Kai Tak construction project which was at the completion stage during FY 2021/22.The data centre leasing business recorded healthy growth in the year under review, representing a testament to the resiliency of the portfolio and right strategy over the years. Revenue derived from its two high-tier data centre buildings, namely iTech Tower 1 and iTech Tower 2 increased approximately 18.4%, from approximately HK$164.7 million for FY 2020/21 to approximately HK$195.0 million for FY 2021/22, primarily driven by increased utilisation of data centre spaces in iTech Tower 2 by committed customers. The Group looks ahead from a position of strength to a focus on growth, and continues to execute the strategy of creating a stable and growing cash flow stream, the Group further diversifies its footprint for high-tier data centres. The two greenfield sites at No.3 On Kui Street and No.8 On Chuen Street in Fanling, the New Territories will be developed into two new high-tier data centres for leasing purposes, with an estimated gross floor area of approximately 185,000 square feet in aggregate. Currently the application for change of land use change of both sites by way of land exchange are in progress. The development at No.3 On Kui Street and No.8 On Chuen Street is scheduled for completion in mid-2025 and mid-2026 respectively.The Group's luxury residential project, CRISTALLO, at No. 279 Prince Edward Road West, Kowloon was well sold. During the year sales of 6 residential units were completed, and revenue of approximately HK$221.7 million was recognized accordingly."The Grand Marine" in Tsing Yi had achieved an encouraging sales performance, with over 92% of the units sold cumulatively. The certificate of compliance of the development was granted in March 2022. Accordingly, handover of the sold units to the buyers commenced from mid-April 2022, with HK$4.75 billion revenue recognised in the first half of our financial year 2022/23. For the property development in Mainland China, the Group acquired its first land parcel in July 2021 through government public auction. The land parcel is located at Guangxi-ASEAN Economic and Technological Development Zone, Wuming District, Nanning City, Guangxi Province. The site has an area of approximately 574,000 square feet, and is planned to be developed into a luxury residential project under the theme of leisure and healthy lifestyle targeting customers at the elderly and retirees and their families. The preliminary design comprises high-rise apartment units, villas, retail shops and a wellness centre. The estimated gross floor area of the proposed development is approximately 1,100,000 square feet. Site clearance works had been completed. Planning and design works are in progress.Mr. Chan Hung Ming, Chairman and Executive Director of Grand Ming Group Holdings concluded, "The achievement of our first property development project of the Grand Marine confirms our successful transition to a property developer which emboldens us to deliver satisfactory results in the coming year. We will continue to launch the sales for the remaining units of the Grand Marine and Cristallo so as to contribute further cash inflows to the Group.""Looking forward, year 2022 remains a year full of challenges conditioned by heightened uncertainty, including potential resurgence of another wave of covid-19 infections, local interest rate hike triggered by the U.S. Federal Reserve's move to hike rates and the global geopolitical tensions. On the other side, resilient demand from the local end-users, limited land supply and low mortgage rate environment continued to support the local residential mass market. We maintain a cautiously optimistic view on the residential property market. Facing with these challenges and uncertainties, we would continue to adopt our prudent approach in managing the Group's businesses and strategies, and searching meticulously for suitable new property development projects both in Hong Kong and Nanning City of Mainland China to build the long-term development roadmap of the Group. The acceleration of digital transformation in business operations and communication among individuals during the pandemic had led to a surge in demand of high-tier data centres and therefore we are committed to developing our two new data centres in Fanling and looking for new pipelines for growth."About Grand Ming Group Holdings Limited (Stock code: 1271.HK)The Group is principally engaged in the business of building construction, property leasing and property development. As a local wholesale co-location provider of high-tier data centres, the Group is one of the dedicated service providers in Hong Kong which owns and uses the entire building for leasing to customers for data centre use. Its clientele includes multinational data centre operator, telecommunications company and financial institutions. The Group operates two high-tier data centre buildings, namely iTech Tower 1 and iTech Tower 2. It also acquired two pieces of land in Fanling, the New Territories for developing into two high-tier data centres. Furthermore, the Group launches a residential development project namely "The Grand Marine" at Sai Shan Road, Tsing Yi, as well as a luxury residential project, Cristallo, at Prince Edward Road West, Kowloon. The Group owns a piece of land at No.1 Luen Fat Street, Fanling, New Territories and a site at No. 41, 43, 45 Pau Chung Street, To Kwa Wan, Kowloon, for developing each into a residential-cum-retail complex with an aggregate gross floor area of approximately 67,000 square feet. In Mainland China the Group owns a piece of land at Guangxi-ASEAN Economic and Technological Development Zone, Wuming District, Nanning City, Guangxi Province with a site area of approximately 574,000 square metres and the estimated gross floor area of the proposed residential development is approximately 1,100,000 square feet.Media Contacts:Angel YeungJovian Communications LtdEmail: news@joviancomm.com Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S. ACN Newswire

SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SM17 in the U.S.

June 15, 2022
HONG KONG, Jun 15, 2022 - (ACN Newswire via SEAPRWire.com) - SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, today announced that, the first healthy subject has been dosed in the Phase I clinical trial of SM17 in the U.S. SM17 is a First-in-Class (FIC) humanized anti-IL-17RB monoclonal antibody. The subject is currently in a normal condition.SM17 is the world's first humanized IgG4-k monoclonal antibody targeting IL-17RB. SM17 is currently under development by SinoMab, and was engineered by LifeArc (a leading medical research charity based in the United Kingdom). SM17 was originally developed by Dr. Andrew McKenzie, FRS, who also serves as a member of the Company's Scientific Advisory Board, at the MRC Laboratory of Molecular Biology (LMB).SM17 could suppress Th2 immune responses by binding to IL-17RB on Type 2 Innate Lymphoid cells (ILC2s), blocking a cascade of responses induced by interleukin-25 (IL-25). IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of airway viral responses and allergic diseases, such as uncontrolled severe asthma. Uncontrolled severe asthma is associated with increased mortality/ morbidity, diminished quality of life and increased health expenditures. These patients are at a risk of recurrent asthma exacerbations and hospitalizations. The Company expected that targeting upstream mediators of the Th2 inflammatory cascade, such as IL-17RB on ILC2s, will have a broad effect on airway inflammation. The Company believes the huge potential of SM17 could satisfy unmet medical needs in asthma treatment. The Phase I study is a Single Ascending Dose (SAD) and Multiple Ascending Doses (MAD) to investigate the safety, tolerability and pharmacokinetics of SM17 in healthy subjects.SM17 received Investigational New Drug (IND) approval from U.S. Food and Drug Administration (FDA) on 11 March 2022. Despite the pandemic, SinoMab have soon initiated the first-in-human dose in the Phase I clinical trial. This marks a significant milestone on the collaboration between SinoMab and LifeArc, and demonstrates the efficient implementation of SinoMab's new drug R&D programs.Melanie Lee, Chief Executive Officer of LifeArc, said: "We applied our antibody capabilities when working with Dr. Andrew McKenzie at the LMB, to firstly generate and select a clinical candidate antibody targeting IL-17RB, and then humanise it. After evaluating and choosing the lead candidate, it was licensed to SinoMab to take forward into clinical development and towards patients. It's so rewarding to know that this antibody is going into trials and could eventually make a difference to people with severe asthma."Dr. Shui On LEUNG, Chairman, Executive Director and Chief Executive Officer of SinoMab said that: "SM17's successful first-in-human dosing in Phase I clinical trial marked another milestone in our pipeline development. Following our flagship product, SM03 and key product, SN1011, we now have another key asset entering the clinical trial stage. This further assures our potential commercialization prospects and proves our capability for progressing multiple assets of R&D concurrently. We are confident of the enormous prospects for SM17's clinical development as well as our commercialization opportunities in general. Moving forward, we will accelerate implementation of our projects, adhere to our vision of independent innovation to bring benefits to patients and create value for shareholders."About LifeArcLifeArc is a self-financing and leading UK medical research charity. It partners and works with academics, industry, charities and patient groups to unlock the potential of early stage science. It has an office in London and scientific research facilities in Stevenage and Edinburgh. It also has a specialist science team working at the Francis Crick Institute in London.About SinoMab BioScience LimitedSinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and is currently in Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), pemphigus vulgaris (PV), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs. Copyright 2022 ACN Newswire. All rights reserved. (via SEAPRWire)
More